- Home
- AVY vs NBIX Comparison
AVY vs NBIX Comparison
Compare AVY & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVY | NBIX |
|---|---|---|
| Founded | 1935 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 15.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | AVY | NBIX |
|---|---|---|
| Price | $186.00 | $135.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 21 |
| Target Price | ★ $204.09 | $177.29 |
| AVG Volume (30 Days) | 658.6K | ★ 1.0M |
| Earning Date | 02-04-2026 | 02-05-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | 5.74 | ★ 12.44 |
| EPS | ★ 8.81 | 4.19 |
| Revenue | ★ $8,770,000,000.00 | $2,682,700,000.00 |
| Revenue This Year | $2.45 | $23.68 |
| Revenue Next Year | $4.28 | $18.47 |
| P/E Ratio | ★ $20.49 | $33.55 |
| Revenue Growth | 1.03 | ★ 19.61 |
| 52 Week Low | $156.23 | $84.23 |
| 52 Week High | $196.41 | $160.18 |
Technical Indicators
Market Signals| Indicator | AVY | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 64.11 | 36.26 |
| Support Level | $179.36 | $134.03 |
| Resistance Level | $183.98 | $142.16 |
| Average True Range (ATR) | 3.08 | 3.13 |
| MACD | -0.18 | -1.09 |
| Stochastic Oscillator | 69.70 | 11.91 |
Price Performance
Historical ComparisonAbout AVY Avery Dennison Corporation
Avery Dennison manufactures pressure-sensitive materials, merchandise tags, and labels. The company also runs a specialty converting business that produces radio-frequency identification inlays and labels. Avery Dennison draws a significant amount of revenue from outside the United States, with international operations accounting for the majority of total sales.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.